Colon delivery system could cut statin doses

Oxford Pharmascience has picked up a delivery system from University College London (U.K.) that could cut statin doses fourfold by delivering the drugs right to the colon. As part of its Safestat program, Oxford Pharmascience will use the delivery system to reformulate, develop and commercialize new versions of Pfizer's ($PFE) atorvastatin and Merck's ($MRK) simvastatin, now both off-patent. The agreement, made through UCL Business, the university's IP licensing arm, is exclusive but terms were not disclosed. It follows a period of evaluation to establish the feasibility of the delivery system and the commercial viability of the products. Press release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…